Kestra Medical Technologies (NASDAQ: KMTS) CFO trades 26,287 shares in 10b5-1 sales

Rhea-AI Filing Summary

Kestra Medical Technologies CFO Vaseem Mahboob reported selling a total of 26,287 Common Shares of KMTS on August 7, 2026 in two open-market transactions under a Rule 10b5-1 trading plan adopted November 6, 2025. The reported sales occurred at weighted average prices of $25.8742 and $26.3300 per share, with detailed price ranges disclosed in the footnotes.

Insider Trade Summary 10b5-1

Net Seller: 26,287 shares

Net Sell 2 txns

Insider Mahboob Vaseem

Role Chief Financial Officer

Sold 26,287 shs ($680K)

Type	Security	Shares	Price	Value
Sale	Common Shares F1, F2	25,787	$25.8742	$667K
Sale	Common Shares F1, F3	500	$26.33	$13K

Holdings After Transaction: Common Shares — 60,609 shares (Direct)

Footnotes (3)

1. F1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2025.
2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.3100 to $26.3050. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
3. F3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $26.3150 to $26.3600. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Key Figures

Shares sold (block 1): 25,787 shares Shares sold (block 2): 500 shares Total shares sold: 26,287 shares +3 more

6 metrics

Shares sold (block 1) 25,787 shares Common Shares sold on August 7, 2026 at weighted average price $25.8742

Shares sold (block 2) 500 shares Common Shares sold on August 7, 2026 at weighted average price $26.3300

Total shares sold 26,287 shares Net shares sold across reported Form 4 transactions (transactionSummary.sellShares)

Price range block 1 $25.3100–$26.3050 Range of actual sale prices for 25,787-share transaction; weighted average $25.8742

Price range block 2 $26.3150–$26.3600 Range of actual sale prices for 500-share transaction; weighted average $26.3300

10b5-1 plan adoption date November 6, 2025 Footnote states trades occurred under Rule 10b5-1 plan adopted on this date

Key Terms

Rule 10b5-1 trading plan, weighted average price, non-derivative, open market or private transaction

4 terms

Rule 10b5-1 trading plan regulatory

"The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price in Column 4 is a weighted average price. The prices at which"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

non-derivative financial

"transaction_type": "non-derivative","transaction_shares":"

open market or private transaction financial

"transaction_code_description": "Sale in open market or private transaction""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/11/2026 - 05:56 PM Accepted by SEC EDGAR 08/11/2026 - 05:56 PM Learn about SEC filing dates

FAQ

What insider transaction did KMTS report for CFO Vaseem Mahboob?

CFO Vaseem Mahboob reported selling a total of 26,287 KMTS Common Shares on August 7, 2026 in two open-market transactions, according to the Form 4 filing’s transaction table and footnotes.

At what prices were the KMTS shares sold by the CFO on August 7, 2026?

The CFO’s KMTS sales used weighted average prices of $25.8742 and $26.3300 per share. Footnotes state actual sale prices ranged from $25.3100–$26.3050 and $26.3150–$26.3600, respectively.

How many KMTS shares did the CFO sell in each Form 4 transaction?

On August 7, 2026, the CFO sold 25,787 Common Shares at a weighted average price of $25.8742 and an additional 500 Common Shares at a weighted average price of $26.3300, as disclosed in the Form 4.

Was the KMTS CFO’s August 7, 2026 share sale under a Rule 10b5-1 plan?

Yes. A footnote states the reported KMTS transactions occurred pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2025, and the Form 4’s Rule 10b5-1 checkbox is affirmed.

Does the KMTS Form 4 show any option exercises or derivative transactions?

No. The Form 4 reports only non-derivative Common Share sales. The structured data show exerciseCount 0, derivativeTransactionCount 0, and an empty derivative positions summary for this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mahboob Vaseem

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/07/2026		S(1)		25,787	D	$25.8742(2)	61,109	D
Common Shares	08/07/2026		S(1)		500	D	$26.33(3)	60,609	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2025.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.3100 to $26.3050. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $26.3150 to $26.3600. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

	/s/ Traci S. Umberger as attorney-in-fact for Vaseem Mahboob	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)